Donald G Grosset

Summary

Affiliation: University of Glasgow
Country: UK

Publications

  1. ncbi Timing the initiation of treatment in Parkinson's disease
    Donald G Grosset
    Institute of Neurological Sciences, Department of Neurology, Southern General Hospital, 1345 Govan Rd, Glasgow G51 4TF, UK
    J Neurol Neurosurg Psychiatry 79:615. 2008
  2. ncbi The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders
    Donald Grosset
    Southern General Hospital, Department of Neurology, Institute of Neurological Sciences, Glasgow, UK
    IDrugs 13:539-42. 2010
  3. ncbi Measuring therapy adherence in Parkinson's disease: a comparison of methods
    K A Grosset
    Institute of Neurological Sciences, Department of Neurology, Southern General Hospital, Glasgow G51 4TF
    J Neurol Neurosurg Psychiatry 77:249-51. 2006
  4. ncbi Dopamine agonists and therapy compliance
    Donald Grosset
    Department of Neurology, Southern General Hospital, Glasgow, G51 4TF, UK
    Neurol Sci 29:S375-6. 2008
  5. ncbi Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease
    Katherine A Grosset
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 20:1397-404. 2005
  6. ncbi Spheramine Titan/Schering
    Donald Grosset
    Southern General Hospital, Department of Neurology, Institute of Neurological Sciences, 1345 Govan Road, Glasgow G51 4TF, UK
    Curr Opin Investig Drugs 6:722-8. 2005
  7. ncbi Suboptimal medication adherence in Parkinson's disease
    Katherine A Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 20:1502-7. 2005
  8. ncbi Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life
    Katherine A Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 20:616-9. 2005
  9. ncbi Prescribed drugs and neurological complications
    K A Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    J Neurol Neurosurg Psychiatry 75:iii2-8. 2004
  10. ncbi Parkinson's disease and related disorders--XVIII WFN World Congress
    Donald Grosset
    Southern General Hospital, 1345 Govan Road, Glasgow, G51 4TF, UK
    IDrugs 13:82-4. 2010

Detail Information

Publications30

  1. ncbi Timing the initiation of treatment in Parkinson's disease
    Donald G Grosset
    Institute of Neurological Sciences, Department of Neurology, Southern General Hospital, 1345 Govan Rd, Glasgow G51 4TF, UK
    J Neurol Neurosurg Psychiatry 79:615. 2008
  2. ncbi The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders
    Donald Grosset
    Southern General Hospital, Department of Neurology, Institute of Neurological Sciences, Glasgow, UK
    IDrugs 13:539-42. 2010
    ....
  3. ncbi Measuring therapy adherence in Parkinson's disease: a comparison of methods
    K A Grosset
    Institute of Neurological Sciences, Department of Neurology, Southern General Hospital, Glasgow G51 4TF
    J Neurol Neurosurg Psychiatry 77:249-51. 2006
    ..How patients take their medicines influences interpretation of the therapy response and consequent management decisions, with implications for clinical trial analysis and clinical practice...
  4. ncbi Dopamine agonists and therapy compliance
    Donald Grosset
    Department of Neurology, Southern General Hospital, Glasgow, G51 4TF, UK
    Neurol Sci 29:S375-6. 2008
    ..The treatment of the syndrome is difficult, hence a strict adherence to antiparkinson medication should be encouraged for prevention...
  5. ncbi Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease
    Katherine A Grosset
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 20:1397-404. 2005
    ..Although the benefits of regularizing oral medicine-taking in a practical, achievable way in PD remain untested, such an approach might prolong and smooth the benefits of oral medication and is worthy of further research...
  6. ncbi Spheramine Titan/Schering
    Donald Grosset
    Southern General Hospital, Department of Neurology, Institute of Neurological Sciences, 1345 Govan Road, Glasgow G51 4TF, UK
    Curr Opin Investig Drugs 6:722-8. 2005
    ..Phase II trials were ongoing in March 2005 and, at this time, were expected to be completed in the second half of 2006...
  7. ncbi Suboptimal medication adherence in Parkinson's disease
    Katherine A Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 20:1502-7. 2005
    ..In conclusion, poorer compliance is associated with younger age, depression, and more tablets per day, and one-fifth of PD patients underuse medication. Consideration of drug therapy adherence has implications in the management of PD...
  8. ncbi Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life
    Katherine A Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 20:616-9. 2005
    ..Due attention to these aspects in delivering care to the PD patient is appropriate...
  9. ncbi Prescribed drugs and neurological complications
    K A Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    J Neurol Neurosurg Psychiatry 75:iii2-8. 2004
  10. ncbi Parkinson's disease and related disorders--XVIII WFN World Congress
    Donald Grosset
    Southern General Hospital, 1345 Govan Road, Glasgow, G51 4TF, UK
    IDrugs 13:82-4. 2010
    ....
  11. ncbi Therapy adherence issues in Parkinson's disease
    Donald Grosset
    Institute of Neurological Sciences, Glasgow, Scotland, UK
    J Neurol Sci 289:115-8. 2010
    ....
  12. ncbi Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland
    Edward J Newman
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    Mov Disord 24:2379-85. 2009
    ..Nearly all of these patients can be identified by simple screening of prescription databases and case records in Primary Care, followed by clinical review, which allows withdrawal of unnecessary medication...
  13. ncbi Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review
    Seema Kalra
    Department of Neurology, Royal Infirmary, University Hospital of North Staffordshire, Stoke on Trent, United Kingdom
    Mov Disord 25:149-56. 2010
    ..The development of accepted international diagnostic criteria for VP is urgently needed to facilitate further studies...
  14. ncbi Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging
    Vicky L Marshall
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    Nucl Med Commun 27:933-7. 2006
    ....
  15. ncbi Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial
    Katherine A Grosset
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    BMC Neurol 7:20. 2007
    ..The effect of informing Parkinson's disease patients about the continuous dopaminergic hypothesis (to encourage regular medicine intake) on medication adherence and motor control was tested...
  16. ncbi Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT
    Vicky L Marshall
    Department of Neurology, Southern General Hospital, 1345 Govan Road, Glasgow, Scotland G51 4TF, United Kingdom
    Mov Disord 24:500-8. 2009
    ..The corresponding baseline [123I]FP-CIT SPECT results showed a mean sensitivity of 78% and a specificity of 97%. Inter-reader agreement for rating scans as normal or abnormal was high (Cohen's kappa = 0.94-0.97)...
  17. ncbi The parkinsonism-hyperpyrexia syndrome
    Edward J Newman
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, G51 4TF, UK
    Neurocrit Care 10:136-40. 2009
    ..Patients and physicians should be warned against sudden reduction in antiparkinson medications. PHS should always be considered in a patient with parkinsonism who presents with an acute deterioration in symptoms...
  18. ncbi Vascular parkinsonism: a clinical review
    Hani T S Benamer
    Department of Neurology, Queen Elizabeth Neuroscience Centre, Queen Elizabeth University Hospital, Birmingham, UK
    Eur Neurol 61:11-5. 2009
    ..There are no widely agreed diagnostic criteria. This article reviews the current literature relating to VP in particular to identify the different clinical presentations that have been described...
  19. ncbi GPI-1485 (Guilford)
    Victoria L Marshall
    Southern General Hospital, Department of Neurology, Institute of Neurological Sciences, 1345 Govan Road, Glasgow G51 4TF, UK
    Curr Opin Investig Drugs 5:107-12. 2004
    ..In August 2002, phase II clinical trials investigating GPI-1485 for Parkinson's disease commenced, and in November 2003, further phase II trials commenced for post-prostatectomy erectile dysfunction...
  20. ncbi Geographical difference in Parkinson's disease prevalence within West Scotland
    Edward J Newman
    University of Glasgow, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 24:401-6. 2009
    ..Exploration of these factors is justified to explain further such wide variation in PD prevalence...
  21. ncbi Parkinson's disease in Arabs: a systematic review
    Hani T S Benamer
    Department of Neurology, Queen Elizabeth Neuroscience Centre, Queen Elizabeth University Hospital, Birmingham, United Kingdom
    Mov Disord 23:1205-10. 2008
    ..The majority of studies relate to the role of genes in the etiology of PD in North African Arabs. Further genetic, epidemiological and clinical studies from the majority of Arabic countries may enhance our understanding of PD...
  22. ncbi Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT
    Vicky L Marshall
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 21:2247-50. 2006
    ..Such cases represent a nondegenerative form of Parkinsonism, which does not benefit from dopaminergic therapy. Prospective vigilance regarding this category is of importance in clinical practice and clinical trials...
  23. ncbi Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders
    Vicky Marshall
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 18:S22-7. 2003
    ..DAT imaging may be particularly informative in monosymptomatic rest tremors, benign tremulous Parkinson's syndrome, and in the elderly in whom essential tremor may be accompanied by pseudoparkinsonism...
  24. ncbi Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations
    Hani T S Benamer
    Neurology Department, New Cross Hospital, Wolverhampton, United Kingdom
    Mov Disord 18:977-84. 2003
    ..When these clinical features are uncertain, or the patient fails clinical diagnostic criteria, testing for dopaminergic deficit with [(123)I]-FP-CIT SPECT may assist the diagnostic process...
  25. ncbi The role of radiotracer imaging in Parkinson disease
    V L Marshall
    Neurology 65:1144-5; author reply 1144-5. 2005
  26. ncbi Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
    Wolfgang H Oertel
    Department of Neurology, Philipps University, Marburg, Germany
    Mov Disord 21:343-53. 2006
    ..In principle, both levodopa and a dopamine agonist such as pergolide seem to be suitable options as initial PD therapy. The choice remains with the treating physician based on the different efficacy and adverse event profiles...
  27. ncbi Dopamine transporter imaging
    Andrew J Lees
    Rita Lila Weston Institute of Neurological Studies, London, United Kingdom
    Mov Disord 18:S1-2. 2003
  28. ncbi Pergolide in Parkinson's disease: time for a change?
    Katherine A Grosset
    Lancet 363:1907-8. 2004
  29. ncbi Proposed dose equivalence for rapid switching between dopamine agonists in Parkinson's disease
    Katherine A Grosset
    Clin Ther 28:1063-4; author reply 1064. 2006
  30. ncbi Turbulence and circulating cerebral emboli detectable at Doppler ultrasonography: a differentiation study in a stenotic middle cerebral artery model
    Yi Yang
    Department of Medicine and Therapeutics, University of Glasgow, Glasgow, England
    AJNR Am J Neuroradiol 23:1229-36. 2002
    ..CONCLUSION: TCD-detectable turbulence predominantly developed at a moderate arterial stenosis and its acoustic signature with TCD is different from that caused by air bubbles and platelet-rich clots...